Related Experiment Videos
[Pathogenic mechanisms in systemic sclerosis and their therapeutical consequences. Part 2: treatment]
J P Zuber1, C Chizzolini, A Leimgruber
1Service d'immunologie et d'allergie Département de médecine CHUV, BH 18/707. jean-philippe.zuber@chuv.ch
Revue Medicale Suisse
|May 23, 2006
Summary
Systemic sclerosis, a severe autoimmune disease, involves immune activation, vasculopathy, and fibrosis. Advances in understanding pathogenesis have led to new treatments improving patient management and outcomes.
Area of Science:
- Rheumatology and Immunology
- Connective Tissue Diseases
- Pathogenesis of Autoimmune Disorders
Context:
- Systemic sclerosis (scleroderma) is a severe connective tissue disease.
- Characterized by abnormal immune activation, vasculopathy, and fibrosis affecting skin and internal organs.
- Recent advancements in understanding disease pathogenesis and identifying key molecules.
Purpose:
- To review the current understanding of systemic sclerosis pathogenesis.
- To highlight novel therapeutic strategies for managing scleroderma.
- To discuss the impact of recent treatments on disease aspects.
Summary:
- Systemic sclerosis involves immune dysregulation, vascular damage, and progressive fibrosis.
- Key molecular targets have been identified, leading to improved treatment options.
- Treatments like ACE inhibitors for renal crisis and cyclophosphamide for lung disease are established.
- Vascular complications such as digital ulcers and pulmonary arterial hypertension are managed with prostaglandins, endothelin antagonists, and PDE5 inhibitors.
Impact:
- Novel treatments significantly improve the management of systemic sclerosis.
- Targeted therapies offer better outcomes for renal, pulmonary, and vascular complications.
- Enhanced understanding of pathogenesis facilitates development of future therapeutic interventions.
Related Concept Videos
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:20The JAK-STAT Signaling Pathway
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
01:14Myocarditis III: Medical Management
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
01:26Nephrotic Syndrome II : Assessment and Medical Management
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document any history...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:26Type I Diabetes II: Pathophysiology
Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...